LONDON – The anti-snoring sleep apnea device SnooZeal has received CE approval and is expecting clearance from the U.S. Food and Drug Administration soon.
“What makes SnooZeal so innovative and effective is that it addresses the root cause of snoring rather than just temporarily relieving it,” said Anshul Sama, creator of SnooZeal, in a statement.
The device sends gentle electronic pulses to the back of the tongue to tone the muscles, which reverses the over-relaxation of the tongue and stops snoring, said Sama. The device is used during the day only and is worn for 20-25 minutes twice a day over a six-week period.
Sama said SnooZeal is unique becaue is addresses the root cause of excessive relaxation and loss of tongue muscle tone during sleep, which obstructs the breathing passage and leads to snoring and sleep apnea. It uses wireless technology to exercise the tongue to treat the physiological cause of snoring and sleep apnea.
A companion smartphone app monitors the user and controls the progress of the treatment.
“It is well known that the long-term effects of sleep deprivation and disturbed sleep can lead to serious health problems,” said Sama.
The company is working on European pre-sales with retailers, ENT consultants, medical device distributors and sleep physicians.
SnooZeal has begun a clinical trial of the device, and expects it to be available over-the-counter in 2017.